Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective dropped by Deutsche Bank Aktiengesellschaft from $1,025.00 to $1,015.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft's price objective indicates a potential upside of 25.91% from the company's current price.
A number of other analysts have also recently weighed in on LLY. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Friday, August 9th. Bank of America dropped their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating for the company in a report on Thursday. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a "buy" rating in a research note on Friday, August 16th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an "overweight" rating in a report on Friday, September 13th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,008.41.
Check Out Our Latest Research Report on LLY
Eli Lilly and Company Stock Performance
LLY traded down $12.79 during trading on Monday, hitting $806.14. The stock had a trading volume of 3,909,568 shares, compared to its average volume of 3,060,016. The firm has a market cap of $765.28 billion, a PE ratio of 87.15, a P/E/G ratio of 3.13 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a 50 day simple moving average of $911.04 and a 200-day simple moving average of $866.97.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 EPS. The company's revenue was up 20.4% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post 13.23 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Twelve Points Wealth Management LLC grew its position in shares of Eli Lilly and Company by 1.4% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company's stock valued at $734,000 after purchasing an additional 11 shares during the period. Verum Partners LLC boosted its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Verum Partners LLC now owns 731 shares of the company's stock valued at $662,000 after buying an additional 11 shares during the period. Beaird Harris Wealth Management LLC increased its position in shares of Eli Lilly and Company by 2.2% during the second quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company's stock worth $464,000 after acquiring an additional 11 shares in the last quarter. Summit Financial Strategies Inc. raised its holdings in shares of Eli Lilly and Company by 0.5% during the third quarter. Summit Financial Strategies Inc. now owns 2,105 shares of the company's stock worth $1,865,000 after acquiring an additional 11 shares during the period. Finally, Prio Wealth Limited Partnership lifted its position in Eli Lilly and Company by 0.5% in the 3rd quarter. Prio Wealth Limited Partnership now owns 2,411 shares of the company's stock valued at $2,136,000 after acquiring an additional 11 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
